MiniMed Group is exploding higher following the release of its fiscal 2027 first-quarter results, which showcased strong momentum across its core business segments. The company reported $843 million in quarterly revenue, representing 15.8% organic growth, while simultaneously highlighting an acceleration in U.S. net sales to 13%. Investors are further reacting to management's updated outlook, which projects approximately 10.5% organic revenue growth for fiscal 2027 as the company prepares for the upcoming U.S. launch of its Fit product line.